Radiation Oncology · Anal Cancer

The Path to Cure: Standard Treatment and the Observation Period

At a Glance

For most anal squamous cell cancers, chemotherapy and radiation are given together first to preserve anal function. The tumor may keep shrinking for about six months, while surgery is considered if a biopsy confirms persistent cancer, the tumor clearly grows, or it returns.

The treatment of anal cancer is a success story for “organ preservation.” In the past, the standard treatment was a major surgery that required a permanent colostomy. Today, thanks to a landmark approach known historically as the Nigro Protocol, the primary goal is to cure the cancer while keeping the anal sphincter intact and functioning ^[1]^[2].

The Gold Standard: Chemoradiation

For most patients with squamous cell carcinoma of the anus, the first-line treatment is definitive chemoradiation ^[3]. This is a coordinated attack on the cancer using two different therapies at the same time:

Radiation Therapy: This is usually delivered daily over 5 to 6 weeks. Modern techniques like Intensity-Modulated Radiation Therapy (IMRT) are preferred because they allow the team to “paint” the radiation onto the tumor and nearby lymph nodes while sparing healthy tissues like the bowel and bladder ^[4]^[5].
Chemotherapy: Two drugs are typically given with the radiation. The standard combination is Mitomycin C (often given on day 1) paired with either infusional 5-Fluorouracil (5-FU) (commonly delivered during defined infusion periods in weeks 1 and 5) or an oral pill called Capecitabine (generally taken on radiation-treatment days) ^[6]^[7]. These regimens have similar success rates, though they carry different side-effect profiles and administration requirements ^[8].

Maintaining the schedule is vital. Evidence suggests that if the total treatment time stretches beyond 42 days, the chances of the cancer returning may increase ^[9]. However, medically necessary holds and dose adjustments sometimes occur. You should never push through dangerous side effects—such as severe skin breakdown, dehydration, uncontrolled diarrhea, inability to urinate, or uncontrolled pain—just to meet an arbitrary date. Promptly report serious side effects so the team can adjust your care safely.

It is also critical to discuss fertility preservation, menopause management, and sexual health with your team before starting chemoradiation, as pelvic radiation can have permanent reproductive effects.

The Observation Period

One of the most unique aspects of anal cancer care is how the body responds to treatment. Unlike some cancers that disappear instantly, anal tumors can be “slow responders.” They may continue to shrink for many weeks after the final dose of radiation is delivered ^[10].

The ACT II trial, a major study in anal cancer, found that while only about 52% of patients had a complete clinical response at 11 weeks, nearly 78% achieved a complete clinical response by 26 weeks (about 6 months) ^[11]. Of those who still had visible disease at the 11-week mark, a significant portion eventually went on to achieve complete response by 26 weeks without any further treatment ^[11].

Because of this, observation for up to approximately six months is a standard approach for clinically nonprogressive disease. Your medical team will perform regular clinical exams to monitor the tumor’s trajectory ^[12]^[13].

When is Salvage Surgery Necessary?

While the goal is organ preservation, surgery remains an essential option. This is referred to as salvage surgery, specifically a procedure called an Abdominoperineal Resection (APR) ^[1].

An APR involves removing the anus, rectum, and part of the sigmoid colon, resulting in a permanent colostomy ^[14]. The timing of salvage treatment is individualized, but is typically considered in specific situations:

Persistent Disease: If a biopsy proves that active cancer cells remain after the observation window ^[15]^[16].
Clear Progression: If the tumor unequivocally grows, or if severe local complications occur, during or shortly after treatment ^[17].
Recurrence: If the cancer achieves a complete clinical response but returns later ^[1].

Before recommending an APR, your doctors will confirm the presence of cancer with a biopsy and perform extensive scans to ensure the surgery can successfully remove all remaining disease ^[14]^[18]. For many, the knowledge that this “plan B” exists provides peace of mind while they undergo the primary chemoradiation treatment.

Common questions in this guide

What is the usual first treatment for anal cancer?

For most people with squamous cell carcinoma of the anus, the first treatment is chemoradiation, meaning radiation given with chemotherapy. Radiation is commonly delivered daily for about five to six weeks, with mitomycin C plus either 5-FU or capecitabine. This approach aims to cure the cancer while preserving anal function.

Why might doctors wait several months after chemoradiation before deciding on surgery?

Anal tumors can be slow to respond and may continue shrinking after radiation ends. If the disease is not clearly getting worse, the team may use regular examinations and observe for up to about six months. Waiting can allow a delayed complete response without immediate surgery.

Does a visible tumor at 12 weeks mean anal cancer treatment failed?

Not necessarily. Some tumors are still shrinking at 12 weeks, so the team considers the examination findings and whether the disease is progressing rather than relying on one time point alone. A biopsy may be needed if cancer remains after the observation period or if the tumor clearly worsens.

When is salvage surgery used for anal cancer?

Salvage surgery may be considered when a biopsy confirms cancer that persists after observation, when the tumor clearly progresses, or when cancer returns after a complete response. The usual operation, called abdominoperineal resection, removes the anus, rectum, and part of the sigmoid colon and requires a permanent colostomy.

Which side effects should I report during anal cancer chemoradiation?

Report serious problems promptly, including severe skin breakdown, dehydration, uncontrolled diarrhea, inability to urinate, or uncontrolled pain. Your team may provide supportive treatment, adjust doses, or pause therapy safely; do not force yourself to continue through dangerous side effects just to meet a planned date. Discuss fertility, menopause, and sexual health before treatment because pelvic radiation can have lasting effects.

Get notified when new evidence is published on anus cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(6)):653-677 doi:10.6004/jnccn.2023.0030.
PMID: 37308125
2
Optimising chemoradiotherapy in anal cancer.
Franco P, Deantonio L, Muirhead R, et al.
ESMO gastrointestinal oncology 2026; (13(Pt A)):100141 doi:10.1016/j.esmogo.2025.100141.
PMID: 42582979
3
Treatment of stage I-III squamous cell anal cancer: a comparative effectiveness systematic review.
Troester A, Parikh R, Southwell B, et al.
Journal of the National Cancer Institute 2025; (117(2)):240-252 doi:10.1093/jnci/djae195.
PMID: 39163501
4
Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
Kachnic LA, Winter KA, Myerson RJ, et al.
International journal of radiation oncology, biology, physics 2022; (112(1)):146-157 doi:10.1016/j.ijrobp.2021.08.008.
PMID: 34400269
5
Radiation Therapy for Anal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.
Feng M, Hallemeier CL, Almada C, et al.
Practical radiation oncology 2025; (15(4)):367-386 doi:10.1016/j.prro.2025.02.001.
PMID: 40023252
6
Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis.
Souza KT, Pereira AA, Araujo RL, et al.
Ecancermedicalscience 2016; (10()):699 doi:10.3332/ecancer.2016.699.
PMID: 28105070
7
Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Oliveira SC, Moniz CM, Riechelmann R, et al.
Journal of gastrointestinal cancer 2016; (47(1)):75-81 doi:10.1007/s12029-015-9790-4.
PMID: 26691173
8
Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Jones CM, Adams R, Downing A, et al.
International journal of radiation oncology, biology, physics 2018; (101(5)):1202-1211 doi:10.1016/j.ijrobp.2018.04.033.
PMID: 29859793
9
Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial.
Glynne-Jones R, Meadows HM, Lopes A, et al.
Annals of oncology : official journal of the European Society for Medical Oncology 2020; (31(10)):1376-1385 doi:10.1016/j.annonc.2020.06.012.
PMID: 32619648
10
Current treatment and future directions in the management of anal cancer.
Tchelebi LT, Eng C, Messick CA, et al.
CA: a cancer journal for clinicians 2022; (72(2)):183-195 doi:10.3322/caac.21712.
PMID: 34847242
11
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
Glynne-Jones R, Sebag-Montefiore D, Meadows HM, et al.
The Lancet. Oncology 2017; (18(3)):347-356 doi:10.1016/S1470-2045(17)30071-2.
PMID: 28209296
12
The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer.
Kochhar R, Renehan AG, Mullan D, et al.
European radiology 2017; (27(2)):607-617 doi:10.1007/s00330-016-4337-z.
PMID: 27090113
13
The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis.
Jones M, Hruby G, Solomon M, et al.
Annals of surgical oncology 2015; (22(11)):3574-81 doi:10.1245/s10434-015-4391-9.
PMID: 25652048
14
Management of Recurrent Anal Cancer.
Littlejohn JB, Brister KA
Surgical oncology clinics of North America 2025; (34(1)):91-101 doi:10.1016/j.soc.2024.07.005.
PMID: 39547772
15
Trends in primary surgery and overall survival in non-metastatic anal cancer: a population-based analysis.
Shen C, Conces M, Ciombor K, et al.
The oncologist 2026; (31(6)) doi:10.1093/oncolo/oyag148.
PMID: 42001213
16
The role of haematological parameters in predicting the response to radical chemoradiotherapy in patients with anal squamous cell cancer.
Stojanovic-Rundic S, Marinkovic M, Cavic M, et al.
Radiology and oncology 2021; (55(4)):449-458 doi:10.2478/raon-2021-0039.
PMID: 34626531
17
Association of Time Between Radiation and Salvage APR and Margin Status in Patients With Anal Cancer Treated With Concurrent Chemoradiation.
Lee GC, Ricciardi R, Stafford C, et al.
The American surgeon 2020; (86(6)):703-714 doi:10.1177/0003134820923326.
PMID: 32683973
18
Long-term oncological outcomes after salvage surgery for anal squamous cell carcinoma - a national cohort study.
Jacobsen S, Angenete E, Johnsson A, et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2026; (52(4)):111482 doi:10.1016/j.ejso.2026.111482.
PMID: 41740517

This page is for informational purposes only and does not constitute medical advice. Your oncology team should tailor chemoradiation, observation, and any salvage surgery to your specific diagnosis, treatment response, and health.